Herpes simplex virus inhibitor - CytoGenix

Drug Profile

Herpes simplex virus inhibitor - CytoGenix

Alternative Names: CY-301; CYGpssXE-59; Simplivir

Latest Information Update: 10 Jan 2008

Price : $50

At a glance

  • Originator CytoGenix
  • Class DNA
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Herpes simplex virus infections

Highest Development Phases

  • Preclinical Herpes simplex virus infections

Most Recent Events

  • 10 Jan 2008 This programme is still in active development
  • 04 Mar 2005 Preclinical data from a media release have been added to the Viral infections pharmacodynamics section
  • 08 Nov 2004 Cytogenix has submitted a pre-IND brief for CY 301 and initiated discussions with the FDA Center for Biologics Evaluation and Research Division of Cellular and Gene Therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top